28 7月 2022 by admin in UncategorizedComments KIRA PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR KP104, A BIFUNCTIONAL ANTIBODY FUSION PROTEIN, FOR THE TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
06 7月 2022 by admin in UncategorizedComments Crescendo Biologics announces nomination of second proprietary clinical candidate from immuno-oncology Humabody VH development portfolio
06 7月 2022 by admin in UncategorizedComments NextCure Announces Development of a Highly Specific Immunohistochemical Diagnostic for Siglec- 15-positive Tumors as reported in Laboratory Investigation
05 7月 2022 by admin in UncategorizedComments Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement
